---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-015516"
form_type: "8-K"
ticker: "BCTX"
cik: "0001610820"
company_name: "BriaCell Therapeutics Corp."
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T03:00:16.815391+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BriaPro Therapeutics (2/3 owned by BriaCell) reports net loss of $519,804 for 9 months, cash only $1

## Summary
- Net loss of $519,804 for nine months ended April 30, 2025 vs. $316,517 in prior year period.
- Accumulated deficit $960,013; cash and cash equivalents $1.
- Due to related parties (BriaCell group) $937,432, up from $424,654 at July 31, 2024.
- Warrant liability revalued to $176,409 from $149,841; change in fair value gain of $26,568.
- Going concern uncertainty: company has not commenced commercial operations and expects further losses.

## SEC filing metadata
- accession: 0001641172-25-015516
- form_type: 8-K
- ticker: BCTX
- cik: 0001610820
- company_name: BriaCell Therapeutics Corp.
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1610820/000164117225015516/0001641172-25-015516-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1610820/000164117225015516/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-015516
- JSON: https://secwatch.observer/filing/0001641172-25-015516.json
- Plain text: https://secwatch.observer/filing/0001641172-25-015516.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.